Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts
02:49am, Thursday, 12'th Feb 2026
CytomX Therapeutics (NASDAQ: CTMX) Chief Financial Officer Chris Ogden outlined the company's current priorities and upcoming catalysts during a fireside chat moderated by Guggenheim senior biotech an
CytomX Therapeutics to Present at Upcoming February Conferences
08:00am, Wednesday, 04'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
07:00am, Tuesday, 27'th Jan 2026
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
03:00pm, Wednesday, 21'st Jan 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)--Wareham Development today confirmed a full floor lease has been signed with CytomX Therapeutics at 5959 Horton Street (EmeryStation West).
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages
06:13am, Tuesday, 20'th Jan 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are presently covering the stock, Marketbeat.com reports. One
CytomX Stock Rises 31% in a Month: Here's What You Should Know
10:21am, Monday, 19'th Jan 2026
CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:36pm, Wednesday, 14'th Jan 2026
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
08:00am, Thursday, 08'th Jan 2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cance
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month High – Still a Buy?
05:46am, Sunday, 04'th Jan 2026
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Friday. The company traded as high as $4.66 and last traded at $4.4450, with a
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of “Moderate Buy” by Brokerages
01:26am, Friday, 26'th Dec 2025
Shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBea
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
01:46am, Monday, 15'th Dec 2025
CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. CTMX also now notes it plans to start combination work with CX-2051 and bevacizumab in Q1'26. F
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:27am, Monday, 01'st Dec 2025
Shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat reports. One an
CytomX Therapeutics to Present at Upcoming December Investor Conferences
08:00am, Tuesday, 25'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage
CytomX Therapeutics: Leaning Into The Hype, But What's Next?
09:32am, Tuesday, 18'th Nov 2025
CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory c
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
08:00am, Thursday, 13'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean M
